Loading
companiesCompany
InventisBio
InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.
Also called: 益方生物
Overview
InventisBio, based in Shanghai, founded in 2013 and listed as 688382.SS, developed garsorasib, one of the two KRAS G12C tablets approved in China in 2024, and the third-generation EGFR inhibitor befotertinib. Garsorasib, or D-1553, was approved in August 2024, befotertinib, or D-0316, was approved in 2023 through Betta Pharmaceuticals for EGFR-mutant non-small-cell lung cancer, and earlier programmes covered gout and oestrogen receptor degraders. OnCo links it to garsorasib and to Betta Pharmaceuticals. Whether a second domestic KRAS G12C inhibitor can differentiate from the other in the same market is the open question. Garsorasib has its own page.
Headquarters
Shanghai, CN
Scorecard
All companies#198of 1244 companies, score 28
- approved products +6
- phase 3 +6
- targets +4
- modalities +2
- regions +1
- registry trials +9
1 approved, 2 in phase 3, 0 earlier, 2 targets, 19 registry studies. Formula on the scorecards page.
Type
Biotech · 688382.SS
Stage
Public
Website
Founded
2013
ApprovedSmall-molecule covalent KRAS G12C inhibitor
Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation.
Phase 3small molecule
IN10018 is an experimental small-molecule drug from InxMed (Shanghai) in phase 3 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer, with its target not yet stated publicly.
Phase 3small molecule
D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Similar pages
- TreatmentIcotinib
Shares Betta Pharmaceuticals and the tag china.
- TreatmentVorolanib
Shares Betta Pharmaceuticals and the tag china.
fronts
drugs
Phase 3small molecule
ApprovedSmall-molecule covalent KRAS G12C inhibitor
Phase 3small molecule
companies
trials
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancera Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid TumorsStudy to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid TumorsStudy to Evaluate D-1553 in Subjects With Solid Tumors